SCHEMBL18157027

SCHEMBL18157027

CCOC(=O)c1c(CO)nc(C)c(C(=O)OC)c1-c1ccccc1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.50
▸ MAPT P10636 5/20 0.50
▸ KDM4E B2RXH2 5/20 0.50
▸ LMNA P02545 4/20 0.50
▸ GAA P10253 3/20 0.50
▸ HPGD P15428 3/20 0.50
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ RAB9A P51151 3/20 0.50
▸ NPSR1 Q6W5P4 2/20 0.50
▸ HTT P42858 2/20 0.50
▸ TSHR P16473 2/20 0.50
▸ NPC1 O15118 2/20 0.50
▸ GRM6 O15303 1/20 0.46
▸ L3MBTL1 Q9Y468 2/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ POLB P06746 1/20 0.44
▸ ALOX5 P09917 1/20 0.44
▸ PDE4B Q07343 1/20 0.44
▸ CDC7 O00311 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20045113 0.87 LMNA (0.45) ALDH1A1MAPTKDM4ELMNAGAA
SCHEMBL18157028 0.87 ALDH1A1 (0.46) ALDH1A1MAPTKDM4ELMNAGAA
SCHEMBL29470061 0.86 HTR1A (0.47) ALDH1A1MAPTKDM4ELMNAGAA
SCHEMBL4632845 0.86 HTR1A (0.47) ALDH1A1MAPTKDM4ELMNAGAA
SCHEMBL30007440 0.86 HTR1A (0.47) ALDH1A1MAPTKDM4ELMNAGAA
SCHEMBL28483296 0.86 HTR1A (0.47) ALDH1A1MAPTKDM4ELMNAGAA
SCHEMBL31231118 0.82 GAA (0.56) ALDH1A1MAPTKDM4ELMNAGAA
SCHEMBL30686655 0.82 GAA (0.56) ALDH1A1MAPTKDM4ELMNAGAA
SCHEMBL6949718 0.82 GAA (0.56) ALDH1A1MAPTKDM4ELMNAGAA
Fumaric Acid SCHEMBL20548498 0.81 HTR1A (0.43) ALDH1A1MAPTKDM4ELMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10265692-B2 Ex vivo methods for predicting and confirming in vivo metabolism of pharmaceutically active compounds EMPIRIKO CORPORATION (US) 2019-04-23 — — US disclosed
US-20160303553-A1 EX VIVO METHODS FOR PREDICTING AND CONFIRMING IN VIVO METABOLISM OF PHARMACEUTICALLY ACTIVE COMPOUNDS EMPIRIKO CORPORATION 2016-10-20 — — US disclosed
US-20160303553-A1 EX VIVO METHODS FOR PREDICTING AND CONFIRMING IN VIVO METABOLISM OF PHARMACEUTICALLY ACTIVE COMPOUNDS EMPIRIKO CORPORATION 2016-10-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160303553-A1 EX VIVO METHODS FOR PREDICTING AND CONFIRMING IN VIVO METABOLISM OF PHARMACEUTICALLY ACTIVE COMPOUNDS CYP3A43, CYP3A4, CYP2D6 ALDH1A1 238/4885MAPT 3807/4885KDM4E 1992/4885
US-10265692-B2 Ex vivo methods for predicting and confirming in vivo metabolism of pharmaceutically active compounds CYP3A43, CYP3A4, CYP2D6 ALDH1A1 238/4885MAPT 3807/4885KDM4E 1992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback